Ryght — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ryght is a private, early-stage technology company providing an AI-powered platform to address inefficiencies in clinical trial site selection and feasibility. Its core innovation is the creation of AI Site Twins, dynamic digital replicas of every clinical research site worldwide, which enable predictive modeling and rapid identification of optimal trial locations. By compressing a process that traditionally takes months into days, Ryght aims to accelerate trial activation, improve enrollment rates, and reduce the overall cost and time of clinical development for pharmaceutical sponsors and CROs. The company appears to be in an early revenue or pre-revenue stage, leveraging partnerships and a presence on the Microsoft Azure Marketplace to drive adoption.

AI / Machine LearningDigital Health

Technology Platform

Generative AI platform that creates 'AI Site Twins'—dynamic, data-derived digital replicas of every clinical research site globally. It uses machine learning to analyze protocols, predict site performance, automate feasibility, and optimize trial execution.

Opportunities

The massive, inefficient clinical trial operations market presents a multi-billion dollar opportunity for AI-driven optimization.

Ryght's therapeutic-area-agnostic platform can scale across all drug development phases and geographies.

Expansion into adjacent use cases like protocol design optimization and real-time trial performance monitoring offers significant growth potential.

Risk Factors

Success depends on acquiring high-quality, comprehensive data to power its AI models, which may be difficult or costly to obtain.

The company faces adoption risk in a traditionally slow-to-change industry and must prove clear ROI to displace entrenched manual processes.

Competition is intensifying from both established CROs and other AI startups.

Competitive Landscape

Ryght competes in the growing Clinical Trial Technology (ClinTech) and AI-for-drug-development space. Direct competitors include other AI-powered site selection startups (e.g., Deep 6 AI, TriNetX in adjacent areas) and the internal digital initiatives of large CROs (IQVIA, Parexel, ICON). It also faces potential competition from broad cloud/AI providers (Google, Amazon) that could develop similar solutions.

More companies in AI / Machine Learning →More companies in United States →